Furiex Pharmaceuticals Inc (FURX)

[surf1944]

7:03AM Furiex Pharmaceuticals confirms Takeda (TKPYY) received European Marketing Authorization for VIPIDIA; MA triggers a $10 mln milestone payment to FURX (FURX) 42.34 : Co confirmed Takeda Pharma's (TKPYY) announcement that the European Commission has granted Marketing Authorization for VIPIDIA (alogliptin) for the treatment of Type 2 diabetes patients who are uncontrolled on existing therapies and for the fixed-dose combinations VIPDOMET (alogliptin and metformin) and INCRESYNC (alogliptin and pioglitazone). The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency, issued a positive opinion for these products on July 26, 2013. Under its agreement with Takeda, the MA triggers a $10 million milestone payment to Furiex. Furiex is also eligible to receive tiered royalties on product sales in the EU and potential sales-based milestones.